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Abstract
Objective: Laser therapy (LT) is considered a safe and effective procedure for inducing 
thyroid nodule necrosis, fibrosis and shrinkage. Little is known about long-term efficacy 
of LT in benign complex thyroid nodules, which we report here.
Design and methods: One hundred and ten euthyroid outpatients (28 men and 82 
women; median age 48 years (range 17–82)) with a recurrent cytologically benign cystic 
(≥2 mL cyst volume) thyroid nodule causing local discomfort were assigned to LT. LT 
was performed after complete cyst aspiration and under continuous ultrasound (US) 
guidance. Nineteen patients (17 within 6 months) had surgery after LT. The median 
follow-up for the remaining 91 patients was 45 months (range: 12–134).
Results: The overall median nodule volume in the 110 patients decreased from 9.0 mL 
(range: 2.0–158.0) to 1.2 mL (range: 0.0–85.0) (P < 0.001) at the final evaluation, 
corresponding to a median reduction of 85% (range: −49 to 100%). Remission of the 
cystic part (volume ≤1 mL) was obtained in 82 of 110 (75%) patients after LT. The median 
cyst volume decreased from 6.3 mL (range: 2.0–158.0) to 0.0 mL (range: 0.0–85.0) 
(P < 000.1), corresponding to a median reduction of 100% (range: −49 to 100%). These 
results correlated with a significant decrease in pressure as well as cosmetic complaints. 
Side effects were restricted to mild local pain.
Conclusion: US-guided aspiration and subsequent LT of benign recurrent cystic thyroid 
nodules results in a satisfactory long-term clinical response in the majority of patients.  
LT constitutes a clinically relevant alternative to surgery in such patients.
Introduction
Thyroid nodules are common in the adult population and 
according to several studies 15–30% of thyroid nodules 
are cystic or predominantly cystic (1). The incidence of 
thyroid cancer in cystic nodules is low and comparable 
or even lower to that of solid cold thyroid nodules (2, 3). 
The vast majority of thyroid cancers are solid or have a 
minimal (1–5%) cystic component (4).
As thyroid carcinomas are rare, the reliance on 
risk stratification systems based on US features and 
fine-needle aspiration (FNA) is essential for an optimal 
management (5, 6). The use of US-guided FNA from 
the solid part of the mixed cystic and solid nodule 
can reduce the number of insufficient biopsies, which 
has been shown to improve the diagnostic accuracy 
(4, 7). Pressure symptoms or cosmetic complaints 
may be an indication for treatment, and nonsurgical 
treatment has been used for several years (8). Although 
simple aspiration of the cystic part may reduce the 
pressure-related symptoms and carries a very low risk 
of side effects, the recurrence rate is on average around 
50% (range: 10–80%), dependent on the number of 
aspirations and the cyst volume (9).
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Over the last decade, US-guided minimally invasive 
ablative therapies have gained widespread attention as 
methods for treating benign thyroid nodules and cysts 
(10, 11, 12, 13, 14, 15). These techniques include thermal 
techniques as well as percutaneous ethanol sclerotherapy 
(PEI). As an alternative to PEI and a way to reduce the 
side effects associated with treating the solid part of 
the nodule (16), LT has, in randomized studies, shown 
promising results (17, 18, 19). However, data on long-term 
efficacy after LT are limited and restricted to solid nodules 
(20, 21). Therefore, we evaluated the remission rate in 
recurrent benign predominantly cystic thyroid nodules 
and nodule-related symptoms in a consecutive group of 
patients treated with LT followed for at least 1 year and on 
average around 4 years.
Patients and methods
One hundred and ten (82 females and 28 males with 
a median age of 48  years (range 17–82)) euthyroid 
outpatients with a cytologically benign, scintigraphically 
cold, and ultrasonographically (US) cystic-solid thyroid 
nodule were assigned to LT. All had cosmetic and/or 
pressure symptoms. Furthermore, all had recurrence 
of the cystic part after the initial diagnostic aspiration. 
Clinically, there was neither suspicion of nor a family 
history of thyroid cancer. None had had prior radiation 
to the neck. Blood tests included serum thyrotropin (TSH) 
(normal range, 0.3–4.0 mU/mL), serum total thyroxine 
(T4) (normal range, 65–135 mmol/L and serum total 
triiodothyronine (T3) (normal range, 1.00–2.10 mmol/L).
LT was carried out on an out-patient basis. At 
enrolment and at the final evaluation, the patients were 
asked to rate pressure symptoms and cosmetic complaints 
on a visual 10 cm analogue scale (0–10), as used a 
multitude of times in previous studies (18, 19, 20, 22). 
The patients were investigated 1, 3 and 6  months after 
the treatment and then annually. Initially, and during 
the follow-up, cyst volume, volume of the solid part and 
total thyroid volume, by US, as well as serum thyroid 
hormones and serum TSH were investigated. Recurrence 
of the cystic part was defined as a volume of more than 
1 mL (determined by US). The initial cyst volume was 
calculated by US, and this result was compared with 
the aspirated volume. The volume of the nodules was 
calculated by measuring the three largest perpendicular 
diameters (length × width × depth × π/6).
LT was performed under sterile conditions, 
guided by US, and preceded by local anesthesia with 
lidocaine (10 mg/mL). The steering needle (18 gauge 
(1.2 mm)) was positioned in the cystic part of the 
thyroid nodule. When this was completely aspirated, 
the steering needle was left in situ and the laser fiber 
(0.4 mm in diameter) was positioned in order to induce 
necrosis and destroy the cyst membrane and the solid 
part of the nodule. The entire procedure was performed 
under continuous US guidance using a high-frequency 
linear transducer (Philips L18-5). The output power 
was between 1.5 and 3.0 W and depended on the size 
of the solid part of the nodule. The laser power source 
was a continuous-wave infrared (820 nm) diode (model 
15; Diomed, Cambridge, England) laser. The vapor was 
clearly visible on US as an irregular hyperechogenic area 
enlarging over time, and the procedure was typically 
terminated when this area was stationary in size or based 
on patient discomfort and/or pain.
The protocol was approved by the Ethics Committee 
of Funen (journal no.81 20070124), and consent has been 
obtained from each patient after full explanation of the 
purpose of the study.
Statistical analyses
Results for continuous data are given as medians and 
ranges. All comparisons for paired data are based 
on ANOVA II (observations based on within-subject 
difference; serial measurements). A backward step-wise 
logistic regression was employed for analyzing potential 
variables predictive for outcome. A P value <0.05 was 
considered significant. Pressure symptoms and cosmetic 
complaints were rated on a 0–10 cm visual analogue scale 
(VAS) and compared with the initial score, and with 
changes evaluated by a sign test. The statistical analyses 
were performed using the SPSS statistical software, 
version 25.0 (SPSS).
Results
The median total energy delivered in the 110 patients was 
1200 J (range: 94–4392), corresponding to 122 J (range: 
14–733) per mL of initial nodule tissue. There was no 
significant difference between the operated group (median 
1200 J (range: 94–4392 J)) and the non-operated group 
(median 1200 J (range: 478–2300)) (P = 0.8). The median 
duration of the LT treatment was 600 s (range: 47–1545). 
The median duration of self-reported symptoms was 
6  months (range: 2–60) and did not differ between the 
operated and non-operated group.
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Treatment outcomes
110 patients, of whom 22 were recruited for a randomized 
trial (19) were assigned to LT (Fig. 1). The overall median 
nodule volume decreased from 9.0 mL (range: 2–158) to 
1.2 mL (range: 0–85) (P < 0.001). Remission of the cystic 
part (volume ≤1 mL) was obtained in 82 of 110 (75%) 
patients after LT. Nineteen patients (17 within 6 months 
and 2 patients after 36 months) had surgery after LT and 
the median follow-up for the remaining 91 patients was 
45 months (range: 12–134).
Results for patients in the surgery group
The decision of subsequent surgery was based on 
persistent nodule-related compressive symptoms 
and/or cosmetic deformity in 19 of 110 patients (17%). The 
median total nodule volume reduction in the 19 patients 
who had surgery decreased from 22.4 mL (range: 5.0–68.0) 
to 19.4 mL (range: 3.0–70.0) (P = 0.05). Median reduction 
in cyst volume was from 20 mL (range: 2.0–68.0) to 18 mL 
(range: 0–70) (P = 0.03) while the solid part diminished 
insignificantly from 2.0 mL (range: 0.0–7.2) to 1.5 mL 
(range: 0.0–10.7) (P = 0.7). In these 19 patients, there was 
neither reduction in self-reported pressure symptoms 
(from median 5.0 (range: 0.0–9.0) to 5.0 (range: 0.0–8.0) 
after LT (P = 0.5)), nor in cosmetic complaints (from 
median 4.0 to 4.0 (range: 0.0–9.0) (P = 0.5)). Although 
there was a significant reduction in cyst- and nodule 
volume, this was insufficient in alleviating the self-
estimated symptoms. Eighteen of these patients had more 
than one cyst aspiration before LT, the median number 
being 3 (range 2–5).
Results for patients in the non-surgery group
The overall median nodule volume in these 91 patients 
decreased from 7.3 mL (range: 2.0–50.0) to 0.8 mL (range: 
0.0–16.1) (P < 0.001) (Fig. 2), corresponding to a reduction 
of 92% (range: −10 to 100%). The median cyst volume 
decreased from 5.5 mL (range: 2.0–45.0) to 0.0 mL (range: 
0.0–5.0) (P < 0.001), corresponding to a median reduction 
of 100% (range: 43–100%), and the solid part decreased 
from 1.6 mL (range: 0.0–17.0) to 0.6 mL (range: 0.0–0.6) 
(P < 0.001) (Fig. 3). Cure of the cystic part, defined as a cyst 
volume ≤1 ml, was achieved in 80 of 91 patients (88%).
In this group, 18 patients had more than one (in fact 
two) aspiration of the cystic part before LT. Eleven patients 
with a cyst volume >1 mL were not cured as for the cystic 
part. Before LT, median cyst volume in these patients was 
10 mL (range 3–40 mL), which decreased to 1.6 mL (range 
1.5–15 mL) (P < 0.05) following LT.
According to self-estimated ratings, on a VAS from 0 
to 10 cm, median pressure symptoms in the 91 patients 
were reduced from 5.0 (range: 0.0–9.0) to 0.0 (range: 
0.0–5.0) (P < 0.001) and cosmetic complaints from 1.0 
(range: 0.0–10.0) to 0.0 (range: 0.0–2.0) (P < 0.001) (Fig. 3).
The only side effect after LT was slight to moderate 
pain in 71 patients. The median duration of the pain was 
2 ± 1.5 days (range: 0–5) treated with mild analgesics in 28 
patients. There were no other side effects such as laryngeal 
nerve injury, fever, haematomas or thyroid dysfunction.
The only parameter which significantly affected the 
cure rate of the cystic part of the thyroid nodule was the 
110 euthyroid paents with a recurrent benign cysc-solid
thyroid nodule
22 paents in randomized
studies
88 paents in non-randomized
studies
19 paents had surgery
(All with benign histology)
91 paents followed ≥ one year; median follow-up was 45 months
(range; 22-134)
Figure 1
Algorithm for enrolment of study patients, in this long-term follow-up 
after LT therapy, for a benign cystic-solid thyroid nodule.
0
1
2
3
4
5
6
7
8
Before LT Final evaluaon
Volume (ml)
P<0.001 (total nodule volume
P<0.001 (cyst volume)
P<0.001 (volume of the solid part)
Total nodule volume
Cyst volume
Volume of the solid part
Figure 2
Total nodule volume, cyst volume and volume of the solid part of the 
nodule before LT and at final evaluation for the 91 patients in the 
non-surgery group (median values).
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number of aspirations before LT, in that a higher number 
of aspirations decreased the chance of success. The 
initial nodule and cyst volume, total energy delivered, 
energy delivered per mL nodule tissue, number of LT 
sessions and treatment duration had no influence on the 
outcome (Table 1).
Discussion
Over the last 10–15  years LT has increasingly, together 
with other thermal ablation techniques, been accepted as 
an alternative to surgery in selected patients with benign 
nodular thyroid disease (13, 18, 19, 23, 24). LT has proven 
efficacious in nonfunctioning thyroid nodules, also in the 
long-term (20, 25). In cystic thyroid nodules, aspiration 
alone may be of therapeutic value, but the effect varies 
considerably, and recurrence is very prevalent and seen in 
up to 80% of patients (1). Levothyroxine is without effect 
(1) and ethanol sclerotherapy, although efficacious (1), 
carries the risk of seepage of the ethanol along the 
needle-tract and potential side effects based on 
extrathyroidal fibrosis and/or affection of the recurrent 
laryngeal nerves (26). The effect of LT in solid nodules is 
well documented but only few studies have reported the 
outcome in cystic-solid (mixed) nodules (26).
In this long-term follow-up study, we show that LT is 
effective in such patients and that the vast majority obtain 
cure of the relapsing cystic part of their thyroid nodule. 
At the final evaluation, a median reduction of the total 
nodule volume of 92% was achieved and remission of 
the cystic part (volume ≤1 mL) was obtained in 82 of 110 
(75%) patients. Furthermore, a significant reduction of the 
solid part of the nodule was also obtained, although this 
was only a small part of the entire complex nodule. Of the 
110 patients, 19 (17%) had subsequent surgery because of 
an unsatisfactory result after LT therapy. This was mainly 
due to unaltered pressure symptoms and/or cosmetic 
complaints and possibly related to the persistence of a 
prominent solid part. Pre-treatment total nodule volume 
in this group with treatment failure was significantly 
larger than in the non-surgery group (median 22.4 mL 
vs 7.3 mL; P < 0.001), but in a multivariate analysis of 
variables affecting treatment success (meaning cure of the 
cystic part), only multiple pre-LT aspirations predicted 
lower success rate. Therefore, results from the current 
study offer little help in selecting which complex nodules 
are the best candidates for LT.
Termination of treatment in each LT session, when 
treating solid nodules, is largely guided by achieving a 
decreased and often obliterated vascularization within 
the nodule. However, in the heterogeneous cystic/solid 
nodules termination relies mostly on the echogenic 
changes not evolving further. This obviously involves 
a large degree of operator-dependent variability and 
is a weakness when defining criteria for a LT treatment 
protocol. Furthermore, if the remnant solid part – after 
the cyst fluid has been emptied – is in close proximity to 
the carotid artery or posterior border, it limits the area 
where positioning the laser fiber will most likely result 
in adequate energy delivered. Increasing output power 
induces burning pain during LT (13) and increases the risk 
of carbonization of the fiber. Moreover, transient vocal 
cord palsy has been described when more than one fiber 
has been used (23). Finally, using two or more fibers results 
in a poorer real-time US overview of the actual extent of 
thermal necrosis and was therefore not considered by us 
in this study.
Pain is the most common complaint during and 
following LT (27, 28). In our studies, pain was mild or 
Table 1 Multivariate analysis of variables affecting treatment 
success (cure of the cystic part ≤1 mL).
 
Variable
Confidence 
interval
 
P value
Total nodule volume 0.86–1.43 0.9
Cyst volume 0.74–1.21 0.7
Previous aspirationa 1.82–5.80 0.001
Total energy delivered 0.99–1.00 0.5
Energy delivered per ml nodule volume 0.99–1.00 0.5
Treatment duration 0.99–1.00 0.5
No of LT sessions 0.3–4.7 0.7
Duration of symptoms 0.16–0.21 0.4
aNumber of aspirations before inclusion.
P<0.001 for both pressure symptoms
and cosme	c complaints aer LT
Visual analogue scale (0 – 10)
Pressure symptoms
Cosmec complaints
10
9
8
7
6
5
4
3
2
1
0
Before LT Final evaluaon
Figure 3
Visual analogue scale for both pressure symptoms and cosmetic 
complaints before and after LT in the 91 patients in the non-surgery 
group (median values).
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moderate and the patients could leave the out-patient 
clinic just after the LT procedure. As opposed to others 
(23, 28), we have not encountered any serious side effects, 
such as damage to the laryngeal nerves, subcapsular 
hematomas or cervical swelling. The explanation could 
be the difference in the output power and a different 
approach by us using only one fiber. In one study, vocal 
cord paresis was reported in 1.6% of treated patients (29), 
but it could be an underestimation as laryngoscopy was 
not routinely performed, in contrast to our practice. 
Importantly, thyroid function was unaltered in all of 
our patients during follow-up and it is also reassuring 
that a benign histology was found in all 19 patients who 
subsequently underwent surgery.
Laser treatment is a low-cost procedure and can be 
performed by a team of one to two physicians and a nurse 
in an out-patient setting. The duration of a complete 
session rarely exceeds 30 min. This definitely favors LT 
to other minimally invasive techniques. Other thermal 
ablation methods, such as radio frequency ablation (RFA), 
has been compared to percutaneous ethanol sclerotherapy 
(PEI), where PEI was superior compared to RFA in cystic 
thyroid nodules (30). Similar volume reduction was 
reported with PEI compared to RFA. However, limitations 
using PEI are the non-predictable diffusion of the ethanol 
in treating the solid part of the nodule, potentially causing 
extraglandular fibrosis and moderate to severe pain (12). 
In disfavor of RFA is the higher expense (30).
In a randomized study, PEI resulted in remission in 
68% of cystic thyroid nodules after one injection (31). 
However, the risk of side effects related to PEI, including 
extraglandular fibrosis, which may impede subsequent 
surgery in case of treatment failure (16, 32), has prompted 
clinical studies on the efficacy of LT in the management 
of relapsing cystic nodules (19, 22). The advantage of LT 
is that the damage can better be restricted to the ablated 
area without extranodular tissue damage. However, RFA 
seems to be superior in reducing the nodule volume 
compared to LT, when applied to solid nodules. Although 
limited, compared to LT, side effects may be more 
common with RFA (19, 20, 27). The main shortcomings 
of these techniques are limited availability, few long-
term follow-up studies and the considerable operator 
dependency, but also the lack of randomized studies 
comparing nonsurgical treatment with surgery (33, 34).
The cure rate of 80% (8 of 10 patients) in a 
pilot LT study (22), followed by short-term data 
from a randomized prospective study (19), as well 
as the present long-term follow-up of 110 patients 
resulting in a cure rate (cyst volume ≤1 mL) of overall 
75% (82 of 110 patients) confirms the efficacy of LT in this 
thyroid phenotype. While LT is not as effective as surgery it 
is a relevant alternative treatment in patients with a solid-
cystic thyroid nodule, extending the data from our group 
(18, 27) and those of Pacella et al. (23). Efficacy is high and 
significantly better than with aspiration alone (18%) and is 
of the order obtained with PEI (31). As opposed to PEI, no 
extranodular damage was observed, and pain was milder, 
whereas the reduction of the solid nodule component was 
preserved, and self-evaluated pressure symptoms vanished 
in the vast majority, resulting in improved quality of life. 
In a retrospective nonrandomized study, RFA performed 
similar to PEI but treatment duration was longer and was 
considerably more expensive (8, 30).
Conclusion
LT is a minimally invasive, safe and low-cost procedure 
resulting in a satisfactory long-term (median 45 months) 
efficacy in four of five patients with a benign cystic-solid 
nodule. It is a clinically relevant alternative to surgery 
in selected patients, not least due to improved patient-
related quality of life and minimal side effects. Therefore, 
we suggest that LT be added to the therapy algorithm for 
this condition as a cost-effective alternative in selected 
patients. The disadvantage is the considerable operator 
dependency and lack of a histological assessment. Future 
studies should focus on comparing minimal invasive 
procedures with surgery and incorporate dedicated 
instruments, such as the ThyPRO (35), for the evaluation 
of quality of life.
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